A novel + microglial subset is identified, driving Alzheimer's disease pathology through neuroinflammation and impaired amyloid-β clearance.
TIM-3 + microglia sustain neuroinflammation via TNF-α/NF-κB and IL-6/JAK/STAT3 signaling pathways.
This microglial subset is associated with impaired amyloid-β clearance linked to PI3K-AKT and FcγR pathways.
Strong interactions were observed between TIM-3 + microglia and known Alzheimer's disease risk genes such as INPP5D and TREM2.
Machine learning analysis classified Alzheimer's patients into a 'hyper-inflammatory' subtype and a 'metabolically dysregulated' subtype, each with distinct pathological drivers.
Network pharmacology analysis predicted tretinoin (ATRA) as a potential therapeutic candidate targeting the CD86–PTPRC–ITGAX axis in TIM-3 + microglia.
Simplified
BACKGROUND: Alzheimer's disease (AD) is characterized by progressive neurodegeneration and neuroinflammation, with microglial dysfunction playing a pivotal role in its pathogenesis. The specific function of the immune checkpoint molecule (encoded by HAVCR2) in microglia remains unclear.
METHODS: We performed an integrated multi-omics analysis combining bulk and single-cell RNA sequencing datasets from AD patients. Bioinformatics approaches, including gene set enrichment, cell-cell communication, and pathway analysis. Furthermore, machine learning algorithms were used to stratify AD patients into molecular subtypes based on HAVCR2 expression. Finally, network pharmacology analysis was conducted to identify potential therapeutic compounds targeting TIM-3 + microglia.
RESULTS: We identified a novel TIM-3 + microglial subset that drives pathogenesis through a dual mechanism: (i) sustained neuroinflammation via TNF-α/NF-κB and IL-6/JAK/STAT3 signaling, and (ii) impaired amyloid-β clearance linked to PI3K-AKT and FcγR pathways. TIM-3 + microglia displayed strong interactions with known AD risk genes such as INPP5D and TREM2. Clinically, machine learning classified AD patients into two molecular subtypes: a "hyper-inflammatory" subtype and a "metabolically dysregulated" subtype, revealing distinct pathological drivers. Network pharmacology predicted tretinoin (ATRA) as a candidate drug targeting the CD86–PTPRC–ITGAX axis in TIM-3 + microglia.
CONCLUSIONS: This study reveals the immunopathological role of TIM-3 + microglia in AD and highlights their contribution to neuroinflammation and impaired protein clearance. The identification of molecular subtypes and a potential drug candidate (ATRA) provides a framework for precision medicine strategies targeting microglial heterogeneity in Alzheimer's disease.
SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12967-025-07621-w.
Key numbers
0.984
AUC of GBM model
Performance of the gradient boosting machine model in training set.
516
Total samples analyzed
Combined samples from four bulk RNA-seq datasets.
356
356 overlapping genes
Overlap between AD-associated genes and tretinoin targets.
Full Text
We can’t show the full text here under this license.
Declarations. Ethics approval and consent to participate: Not applicable. Consent for publication: Not applicable. Competing interests: All the authors declare that they have no competing interests.